Hansa Biopharma Reports First Patient Treatment of Imlifidase in P-II Study for ANCA-Associated Vasculitis
Shots:
- The first patient has been treated in an investigator-initiated P-II study evaluating imlifidase (IgG-cleaving enzyme) in patients with ANCA-associated vasculitis. The trial was led by Dr. Adrian Schreiber & Dr. Philipp Enghard at Charité Universitätsmedizin, Berlin, Germany
- The primary objective of the study is to assess the efficacy & safety of imlifidase with SoC by evaluating ANCA Ab seroconversion and titers, AEs, mortality, amelioration of lung and renal function over a 6mos. observation period for pulmonary hemorrhage due to sev. ANCA-associated vasculitis
- The clinical trials in anti-glomerular basement membrane disease & GBS have shown that imlifidase has the potential to address areas of significant unmet need in the autoimmune disease
Ref: PR Newswire | Image: Hansa
Related News:- Hansa Biopharma Receives Positive Reimbursement Decision for Idefirix (imlifidase) in the Czech Republic
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
